Why Do Men with Prostate Cancer Discontinue Active Surveillance for Definitive Treatment? A Mixed Methods Investigation

Overview

Journal Psychooncology

Publisher Wiley

Specialties Oncology
Psychology

Date 2022 May 11

PMID 35538736

Authors

Megan McIntosh

Melissa J Opozda

Michael OCallaghan

Andrew D Vincent

Daniel A Galvao

Camille E Short

Affiliations

Soon will be listed here.

Abstract

Objectives: To explore the personal and/or medical reasons patients on active surveillance (AS) have, or consider having, further definitive treatment for their prostate cancer. Research suggests up to 50% of patients on AS will discontinue within 5 years, though reasons for discontinuation from the patient's perspective is under-explored.

Methods: Prostate cancer patients who were or had been on AS for at least 6 months were recruited. A questionnaire assessed reasons for receiving/considering definitive treatment and the extent to which reasons were personal or medical. Clinical information was extracted from a state-level population registry. A subset of participants were interviewed to further explore questionnaire responses.

Results: One-hundred and-three individuals completed the survey; 33 were also interviewed. Fifty-four survey participants (52%) had discontinued AS for definitive treatment. Common reasons for discontinuation were evidence of disease progression, doctor recommendation, desire to act, and fear of progression. Many participants who considered or had treatment reported weighing medical and personal factors equally in their decision. Interview participants described strongly considering any amount of disease progression and personal factors such as fear of progression, family concerns, and adverse vicarious experiences when deciding whether to pursue treatment.

Conclusion: Both medical and personal factors are considered when deciding whether to discontinue AS. Identifying predictors of discontinuation is essential for informing supportive care services to improve AS management.

Citing Articles

Multi-level Factors to Build Confidence and Support in Active Surveillance for Low-Risk Prostate Cancer: A Qualitative Study.

Chen J, Subramanian L, Skolarus T, Hawley S, Rankin A, Fetters M J Gen Intern Med. 2025; .

PMID: 39870995 DOI: 10.1007/s11606-024-09345-x.

Personalized Dynamic Prediction Model for Biopsy Timing in Patients With Prostate Cancer During Active Surveillance.

de Vos I, Nieboer D, Frydenberg M, Pavlovich C, Van Hemelrijck M, Lee L JAMA Netw Open. 2025; 8(1):e2454366.

PMID: 39820695 PMC: 11739991. DOI: 10.1001/jamanetworkopen.2024.54366.

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing.

Lenz L, Clegg W, Iliev D, Kasten C, Korman H, Morgan T Prostate Cancer Prostatic Dis. 2024; .

PMID: 39237680 DOI: 10.1038/s41391-024-00888-y.

The association between fear of progression and medical coping strategies among people living with HIV: a cross-sectional study.

Li B, Lin X, Chen S, Qian Z, Wu H, Liao G BMC Public Health. 2024; 24(1):440.

PMID: 38347483 PMC: 10860317. DOI: 10.1186/s12889-024-17969-1.

Incidence profile of four major cancers among migrants in Australia, 2005-2014.

Yu X, Weber M, Smith D, Velentzis L, Kliewer E, David M J Cancer Res Clin Oncol. 2023; 149(11):8317-8325.

PMID: 37072554 PMC: 10374701. DOI: 10.1007/s00432-023-04764-5.

References

Kinsella N, Helleman J, Bruinsma S, Carlsson S, Cahill D, Brown C . Active surveillance for prostate cancer: a systematic review of contemporary worldwide practices. Transl Androl Urol. 2018; 7(1):83-97. PMC: 5861285. DOI: 10.21037/tau.2017.12.24. View

Nilsson R, Naess-Andresen T, Myklebust T, Bernklev T, Kersten H, Haug E . Fear of Recurrence in Prostate Cancer Patients: A Cross-sectional Study After Radical Prostatectomy or Active Surveillance. Eur Urol Open Sci. 2021; 25:44-51. PMC: 8317872. DOI: 10.1016/j.euros.2021.01.002. View

Tauber N, OToole M, Dinkel A, Galica J, Humphris G, Lebel S . Effect of Psychological Intervention on Fear of Cancer Recurrence: A Systematic Review and Meta-Analysis. J Clin Oncol. 2019; 37(31):2899-2915. PMC: 6823887. DOI: 10.1200/JCO.19.00572. View

Punnen S, Cowan J, Dunn L, Shumay D, Carroll P, Cooperberg M . A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013; 112(2):E67-75. DOI: 10.1111/bju.12209. View

Ruseckaite R, Beckmann K, OCallaghan M, Roder D, Moretti K, Millar J . A retrospective analysis of Victorian and South Australian clinical registries for prostate cancer: trends in clinical presentation and management of the disease. BMC Cancer. 2016; 16:607. PMC: 4974765. DOI: 10.1186/s12885-016-2655-9. View

Venderbos L, van den Bergh R, Roobol M, Schroder F, Essink-Bot M, Bangma C . A longitudinal study on the impact of active surveillance for prostate cancer on anxiety and distress levels. Psychooncology. 2014; 24(3):348-54. DOI: 10.1002/pon.3657. View

Lang M, Tyson M, Alvarez J, Koyama T, Hoffman K, Resnick M . The Influence of Psychosocial Constructs on the Adherence to Active Surveillance for Localized Prostate Cancer in a Prospective, Population-based Cohort. Urology. 2017; 103:173-178. PMC: 5410889. DOI: 10.1016/j.urology.2016.12.063. View

Bokhorst L, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma C . A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment. Eur Urol. 2016; 70(6):954-960. DOI: 10.1016/j.eururo.2016.06.007. View

Hamdy F, Donovan J, Athene Lane J, Mason M, Metcalfe C, Holding P . 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016; 375(15):1415-1424. DOI: 10.1056/NEJMoa1606220. View

10.

Sanda M, Cadeddu J, Kirkby E, Chen R, Crispino T, Fontanarosa J . Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. J Urol. 2017; 199(3):683-690. DOI: 10.1016/j.juro.2017.11.095. View

11.

McIntosh M, Opozda M, OCallaghan M, Vincent A, Galvao D, Short C . Why do men with prostate cancer discontinue active surveillance for definitive treatment? A mixed methods investigation. Psychooncology. 2022; 31(8):1420-1430. PMC: 9540004. DOI: 10.1002/pon.5947. View

12.

Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos L . How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol. 2014; 67(4):637-45. DOI: 10.1016/j.eururo.2014.10.028. View

13.

Ruane-McAteer E, Porter S, OSullivan J, Dempster M, Prue G . Investigating the psychological impact of active surveillance or active treatment in newly diagnosed favorable-risk prostate cancer patients: A 9-month longitudinal study. Psychooncology. 2019; 28(8):1743-1752. DOI: 10.1002/pon.5161. View

14.

Hall D, Luberto C, Philpotts L, Song R, Park E, Yeh G . Mind-body interventions for fear of cancer recurrence: A systematic review and meta-analysis. Psychooncology. 2018; 27(11):2546-2558. PMC: 6488231. DOI: 10.1002/pon.4757. View

15.

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

16.

Kinsella N, Stattin P, Cahill D, Brown C, Bill-Axelson A, Bratt O . Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. Eur Urol. 2018; 74(3):261-280. PMC: 6198662. DOI: 10.1016/j.eururo.2018.02.026. View

17.

Kinsella N, Beckmann K, Cahill D, Elhage O, Popert R, Cathcart P . A Single Educational Seminar Increases Confidence and Decreases Dropout from Active Surveillance by 5 Years After Diagnosis of Prostate Cancer. Eur Urol Oncol. 2019; 2(4):464-470. DOI: 10.1016/j.euo.2018.09.007. View

18.

van den Bergh R, Essink-Bot M, Roobol M, Schroder F, Bangma C, Steyerberg E . Do anxiety and distress increase during active surveillance for low risk prostate cancer?. J Urol. 2010; 183(5):1786-91. DOI: 10.1016/j.juro.2009.12.099. View

19.

Harris P, Taylor R, Minor B, Elliott V, Fernandez M, ONeal L . The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. PMC: 7254481. DOI: 10.1016/j.jbi.2019.103208. View

20.

Palinkas L, Horwitz S, Green C, Wisdom J, Duan N, Hoagwood K . Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health. 2013; 42(5):533-44. PMC: 4012002. DOI: 10.1007/s10488-013-0528-y. View